After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
669-FO) inhibits Recombinant Human/Mouse/Rat Activin A (Catalog # 338-AC) induced hemoglobin expression in the K562 human chronic myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by psuedoperoxidase activity. Inhibition of Recombinant Human/Mouse/Rat Activin A (7.5 ng/mL) activity elicited by Recombinant Human Follistatin 300 (0.4 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human/Mouse Follistatin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF669). At 6 µg/mL, this antibody will neutralize > 60% of rhFollistatin 300 bioactivity." class="big_lightbox" target="_blank">
CTS002) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." class="big_lightbox" target="_blank">
DY990). Mouse Anti-Human Follistatin Monoclonal Antibody (Catalog # MAB6692) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994)." class="big_lightbox" target="_blank">
Species: Hu Applications: ELISA Host: Mouse Monoclonal
FST, also known as Follistatin, has a 344 amino acid long isoform that is 38 kDa and a short 317 amino acid that is 35 kDa, functions as an activin antagonist binding directly to it and inhibits the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). Studies of this protein are being performed in relation to polycystic ovary syndrome, pituitary adenoma, insulin resistance, Down syndrome, plasmacytoma, lymphocytic leukemia, pituitary tumor infertility, endometrial carcinoma, teratocarcinoma, azoospermia, meningitis, hepatocellular carcinoma, ovarian carcinoma, liver disease, endometriosis, prostate carcinoma, prostatitis, ovarian cancer, and adenoma. This protein has been also shown to have interactions with ANG, DIP2A, BMP4, FN1, and TXN in signal transduction activin A signaling regulation and TGF-beta signaling pathways.